日期: 2024年8月30日

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com)  Beijing Tong Ren Tang Chinese Medicine Company Limited (“Tong Ren Tang Chinese Medicine” or the “Company”, Stock code: 3613.HK) is pleased to announce the unaudited results of the Company and its subsidiaries (collectively referred to as the “Group”) for the six months ended 30 June 2024 (the “Period”).In the first half of 2024, facing challenges such as the sustained strength of the Hong Kong dollar, changing consumption patterns, and a sluggish retail industry in Hong Kong, China and Macau, China regions, the Group responded proactively and made simultaneous efforts from multiple dimensions of products, marketing, research and development, and production. This ensured the stable operation of its business and the continued consolidation of its market-leading position. During the Period, the Group achieved revenue of HK$ 664.5 million, net profit of HK$ 240.3 million, and profit attributable to owners of HK$ 219.8 million, with earnings per share of HK$ 0.26.By market segment, during the Period, the Group further enriched its product matrix and optimized its retail market layout. The Hong Kong, China market achieved revenue of HK$333.8 million, with 30 retail terminals, a net increase of 3 terminals compared with the previous year. In the markets outside Mainland China (excluding Hong Kong, China,), the Group accelerated its brand market expansion and steadily promoted its internationalization, achieving revenue of HK$214.4 million. In addition, the Group achieved revenue of HK$116.3 million in Mainland China market.Sufficient momentum from technological innovation, new breakthroughs in production and R&DThe development of science and technology has provided new technical support and growth strategies for the advancement of traditional Chinese medicine (“TCM”). During the Period, the Group leveraged technological innovation as a driving force, empowering intelligent upgrades in production and enhancing product excellence and innovation. This has helped accumulate new momentum for future growth and supported the inheritance and innovation of TCM.Product quality is the lifeline of an enterprise. At the production level, the Group’s production and R&D base in Tai Po consistently upholds stringent standards and rigorous procedural controls. The Group has successfully secured Hong Kong, China’s GMP and ISO22000 certifications, with its product quality has been recognized. Additionally, to further enhance the cost competitiveness of its products, the Group has intensified efforts in revamping and upgrading its production layout. By increasing mechanization and automation, the Gorup has effectively reduced production costs and boosted productivity, thereby ensuring consistent product availability in the market.In terms of products, the Group intensifies its R&D efforts, actively diversifying its product matrix and expediting the translation of scientific research outcomes. During the Period, the Group completed the production of a number of new registered proprietary Chinese medicines and health food products, including Guizhi Fuling Wan , Lingzhi Turmeric Compound Blood-supplementing and Nerve-calming Capsules , Wolfberry Coffee Mix , Red Ginseng Coffee Mix  and Sporoderm-broken Ganoderma Lucidum Spores Chocolate . The Group also plans to commence the production of Qiyao Pills ) and Jinshui Liujun Jian Granules. In April this year, the Group’s self-developed product, Danggui Buxue Keli, were awarded the Certificate of Registration of Proprietary Chinese Medicines (HKC-18604) issued by the Chinese Medicine Council of Hong Kong, China, further enriching the Group’s product portfolio. In May this year, the Group’s invention patent (Patent Number: ZL 2023 1 1206874.8) for “a freckle-removing and whitening product along with its preparation method and uses was successfully granted by China National Intellectual Property Administration and has been applied to Ageing-Defying Collection of the Tong Ren Tang’s Chinese anti-aging NMN series.In addition to preserving and advancing TCM services, the Group is also expanding into new health concept areas. During the Period, the Group entered into a Memorandum of Understanding with Deer Industry New Zealand to promote innovative health-functional deer food products, assisting both parties in collaborative development, registration and marketing efforts. The Group will give full play to strengths in both its proprietary brand and Chinese medicine, combined with the resource advantages provided by New Zealand, the origin of deer velvet, to accelerate the R&D of New Zealand deer products and the deployment of the industrial chain configuration, and continue to expand into new health domains.Moving forward, the Group will continue to strengthen its cooperation with internationally renowned institutions and research organizations such as the University of Hong Kong, Hong Kong Baptist University and the University of California, to conduct research on the safety and mechanism of key products such as Tong Ren Tang’s Angong Niuhuang Wan , Ganoderma Lucidum-related products and Tong Ren Niu Huang Qing Xin Wan, in order to further expand its scientific research results, and to provide a reliable scientific basis for the entry of its products into the mainstream markets overseas in the future. The Group adheres to the highest standards of superior, pure and genuine traditional Chinese medicinal materials, and brings together the essence of the intangible cultural heritage culture and exquisite craftsmanship, as well as strict and meticulous production to fully embody the Group’s motto: “Never cut corners on labour and quality, no matter how complex the process or how costly the materials”. This philosophy not only enhances the health value delivered to customers but also provides the Group with a stronger growth momentum.Orderly market expansion and diversified marketing to strengthen brand effectIn terms of market expansion, on the one hand, the Group has continuously introduced new products to consolidate and expand its market share. During the Period, the Group launched new products, including the Tong Ren Tang’s Chinese anti-aging NMN series – the Youth Prime Collection  and the Age-Defying Collection, the Guizhi Fuling Wan , and Wood Lok Medicated Oil , broadening its product range. At the same time, the Group further expanded its retail presence in Hong Kong, China by opening three new retail outlets in North Point, Mong Kok, and West Kowloon. The North Point and West Kowloon stores also offer Chinese medical consultation and treatments to reach a wider customer base.In terms of product marketing, the Group has intensified its marketing efforts to increase product recognition. Specifically targeting the “major variety” products, such as Tong Ren Tang Angong Niuhuang Wan and Sporoderm-broken Ganoderma Lucidum Spores Powder Capsule and Tong Ren Niu Huang Qing Xin Wan, the Group promoted and advertised the brand and products through an omni-channel approach, integrating special festivals and themes to create consumer hotspots. Moreover, the Group has also advanced the development of both online and offline channels, continuously expanding its sales channels to meet the demands of post-pandemic era business models.In terms of brand promotion, the Group capitalized on its participation in major events, significantly enhancing its promotional efforts and accelerating the brand market expansion. During the Period, serving as a critical portal for Beijing Tong Ren Tang’s international development, the Group participated in the 2024 Wuzhen Health Conference, showcasing its flagship products and a variety of new products. In implementing the “Belt and Road” initiative, the Group leads time-honored brands venture into the world and integrates into the international arena. By adopting the “bring in” and “go global” strategy, the Group is promoting the rich and profound TCM culture, further disseminates Chinese health wisdom globally to benefit more people.Additionally, the Group has enhanced its brand image and influence through public welfare activities. The Group has actively encouraged its overseas retail outlets that offer Chinese medical consultations and treatments to provide charity Chinese medicine clinic services. This initiative embodies the Group’s philosophy of “introducing medicine through treatments” and supports its brand development. In Hong Kong, China, the Group has fully supported and participated in public welfare activities, demonstrating to society and the public the Group’s corporate spirit of “Nurturing kindness and virtue, preserving tranquility and wellness ”. Through its services and products, the Group is dedicated to deeply embedding the Tong Ren Tang brand, products and Chinese medical consultation and treatments services into the community, spreading the culture of Tong Ren Tang while encouraging a healthy lifestyle among community residents.Future ProspectsWith the ongoing economic and social development, an intensifying aging population trend, and the increasing health awareness among residents, the pharmaceutical consumption market is expected to expand continuously. TCM, as a crucial sector of the pharmaceutical industry, continues to hold significant potential for growth in the global market.In the future, the Group will continue to strengthen R&D efforts and expand its proprietary product matrix, including products such as Ganoderma Lucidum series and anti-aging series, to create diversified growth engines and drive the realization of high-quality developmental transformation within the Group. At the same time, the Group will focus on business development by enhancing its new retail layout, accelerating the introduction of new products, continuously advancing the registration of Tong Ren Tang’s key products in Vietnam, innovating business models, and reinforcing its core competitive advantages. By leveraging the development of new quality productive forces as its engine, the Group strives to achieve sustained growth in its business scale. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - Liuzhou, a key industrial hub in Southwest China, has long been a pioneer in China's industrial history. From manufacturing Guangxi's first automobile and aircraft before the founding of the People's Republic of China to becoming the second-largest industrial city in South China during the reform era, Liuzhou has consistently thrived with the times.Today, as Chinese automotive companies expand globally, Liuzhou's businesses are once again at the forefront, with Wuling Motors (0305.HK) serving as a prominent example.On August 22, Wuling Motors announced its interim results for 2024, demonstrating strong performance across its three main business segments. The company is actively enhancing its high-quality production capabilities and exploring growth opportunities abroad, achieving impressive results in its international ventures.In the first half of 2024, Wuling Motors made significant strides in its overseas expansion: exporting auto parts to Vietnam, golf carts to Egypt, and new energy logistics vehicles to South Korea, as well as establishing a research and development center in Hong Kong...Wuling Motors is sending a clear message to the world: The company's future is bright, with limitless potential.(I) Moderate Growth in Auto Parts and Other Industrial Services RevenueAccording to Wuling Motors' 2024 interim report, the company achieved a revenue of CNY 3.946 billion in the first half of this year, with a gross profit of CNY 426 million. Net profit surged 72.3% to CNY 21.125 million compared to the same period last year.Breaking down the segments, the auto parts and other industrial services business recorded a revenue of CNY 2.698 billion in the first half of the year, up 6.1% year-on-year. During this period, Wuling Motors focused on consolidating its existing market while aggressively expanding into new territories. The company aimed to break into growth markets dominated by giants like Great Wall Motors, Chery, and BYD. Sales to newly acquired customers surged to CNY 1.042 billion, accounting for 38.6% of the divisional revenue.Wuling's Jingmen base in Hubei, dedicated to supplying Great Wall Motors, rapidly scaled up its production, generating CNY 334 million in revenue in the first half of the year. It successfully delivered frame assemblies for two Great Wall models, breaking the record for the highest first-month delivery of a new product. Additionally, Wuling's domestic ultra-high-strength steel tube hydroforming production line - a first in China - successfully commenced mass production, supplying 13 hydroformed products to premium models from brands like Great Wall and BYD.The auto parts and other industrial services segment posted an operating profit of CNY 75.883 million in the first half of the year, up 44.3% year-on-year.In the automotive power systems segment, Wuling Motors achieved CNY 902 million in revenue. While strengthening its traditional power technology upgrades, Wuling Motors accelerated its layout of new energy power integration development, speeding up its new energy business initiatives. In the first half of 2024, Wuling accelerated the establishment of a comprehensive product matrix for hybrid and battery electric powertrains and core components, advancing production capacity and rolling out new products and technologies. By promoting its products, Wuling Motors has focused on building lines and improving processes for motors, motor controllers, rotors, and stators, securing new energy market collaborations with JAC Motors and Changan Kaicene.The commercial vehicle segment posted CNY 331 million in revenue in the first half of the year, primarily seeking breakthroughs in high-value-added sub-sectors.Wuling Motors achieved a gross profit margin of 10.8% in the first half of 2024, a significant increase of 270 basis points from 8.1% in the same period in 2023. This impressive growth was largely driven by declining prices for raw materials, such as steel. Additionally, the ramp-up of higher-margin products further contributed to the substantial improvement in the company's profitability.(II) Striking the Main Chord of Overseas ExpansionIn the 1960s and 1970s, Liuzhou's tractors were exported to Vietnam and Rwanda in Africa, and in 1990, its microcars were shipped to Thailand. Liuzhou-made vehicles have consistently ventured overseas.Today, Liuzhou's automotive industry faces another historic opportunity for overseas expansion.As domestic market demand becomes saturated, expanding abroad has become essential for Chinese companies, and overseas markets are emerging as the new "blue ocean."For example, Guangxi's exports were robust in the first half of the year. According to customs statistics, Guangxi's import and export trade reached CNY 345.28 billion in the first half of 2024, up 12% year-on-year. Exports alone hit CNY 191.8 billion, a record high, rising 28.5%. Exports of major categories like mechanical and electrical products and labor-intensive products were CNY 109.18 billion and CNY 37.3 billion, respectively, growing by 26.8% and 48.5% and accounting for 56.9% and 19.4% of Guangxi's total exports.In the automotive market, "intense competition" and "overseas expansion" are the current hot topics. According to the China Association of Automobile Manufacturers (CAAM), in July 2024, China exported 469,000 vehicles, up 19.6% year-on-year. From January to July 2024, China's auto exports reached 3.262 million units, up 28.8%. Among these, exports of battery electric vehicles totaled 554,000 units, and plug-in hybrid vehicles reached 154,000 units, representing a 180% increase year-on-year.Specifically in Liuzhou, more than 90,000 vehicles were exported through Liuzhou Customs in the first half, up 23.8% year-on-year; of these, over 10,000 were new energy vehicles (NEVs), a surge of more than 30-fold.Wuling Motors has seized this trend, charting a course for global success.Take the Wuling golf cart as an example. With its strong handling, lightweight design, comfortable ride, and powerful performance, the Wuling golf cart has been highly favored by overseas customers. Since its launch, it has been sold in countries across Southeast Asia, Central Asia, Europe, and America.Earlier this year, Wuling Industrial, a subsidiary of Wuling Motors, showcased its new multi-purpose golf/community vehicles at the 71st PGA Merchandise Show in Orlando, USA, drawing significant attention. On April 15, the 135th Canton Fair kicked off in Guangzhou, where Wuling Industrial's golf carts attracted buyers from 205 countries and regions worldwide. On May 22, Wuling Industrial shipped about 200 golf carts to Egypt, expecting to complete delivery in the third quarter.Wuling Motors' joint venture, Wuling New Energy, also broke new ground with its G050 left-hand drive battery electric logistics vehicle. In March 2024, the company secured its first order of 300 units with South Korea's Daechang Corp, marking a breakthrough in the Korean market.Currently, Wuling's sightseeing vehicles, golf carts, and other products are exported to countries such as Vietnam, Singapore, Thailand, the USA, and Australia. Its new energy logistics vehicles have also penetrated traditional automotive powerhouses or regions such as the USA, Japan, and Europe, laying a solid foundation for expanding into the international market.This achievement is due to Wuling Motors' strategic planning.In recent years, Wuling Motors has accelerated its overseas expansion, with subsidiaries in India and Indonesia continuing to strengthen their presence. These efforts, focused on promoting the localization and launch of new models with key clients, have proven highly effective, helping Wuling penetrate new customer bases and meet international standards.On the product side, Wuling Motors has further enriched its product lineup, with more auto parts poised to enter global markets. In a major breakthrough, Wuling's self-developed rear drive axle assembly and drive system assembly for new energy passenger vehicles successfully entered the overseas market in the first half of this year. This achievement marks a departure from the traditional three-section axle housing structure, instead adopting a hydraulic expansion integral axle housing technology, which has been well-received by customers. On the channel side, Wuling is leveraging Hong Kong as an export conduit for its new energy business, boosting overseas sales for the group and its joint ventures.On the research and development front, Wuling Motors has established an innovation center in Hong Kong and signed memoranda of understanding (MOUs) with Hong Kong Polytechnic University (PolyU) and the Chinese University of Hong Kong (CUHK) to focus on NEV technology, jointly promoting the conversion and application of scientific research results.(III) Driving Global Growth Through High-Quality ProductionIn global competition, technology reigns supreme. Wuling Motors has been a pioneer in the NEV sector, steadfastly pursuing the development of NEVs. With a goal of deriving more than 50% of its business from NEV operations, Wuling is laying a solid foundation to become a front-runner in the new energy vehicle era as it ventures into overseas markets.In the auto parts business, Wuling Motors continues to align with the "passenger-focused" and "electrification" upgrades of its customers' products, continuously developing passenger vehicle products while actively supporting new energy vehicle models for major customers.Currently, Wuling Motors has successfully developed and optimized a range of products, including new energy electric rear axles, motors, motor controllers, range extenders, and hybrid systems. This year, the production of core components such as electric axles and hybrid engines has seen steady growth.After surpassing the milestone of producing one million units of micro electric axles, Wuling's coaxial electric drive axle became the first to achieve commercialization in China. It has been adopted by brands such as Changan Kaicene, Ruichi, and JAC Motors. Wuling Motors also secured orders from leading companies like Chery and Geely for electric axles used in mainstream NEV commercial vehicles. At Wuling's Jingmen base, which supplies auto parts to Great Wall Motors, business has flourished, with over 50% of its products sold in the first half of 2024 being NEV parts, generating CNY 333 million in revenue.In automotive power systems, Wuling Motors has made remarkable progress in developing and mass-producing high-efficiency engines and new energy power systems. Their strategy seamlessly integrates traditional power technology upgrades with new energy power innovations, resulting in a robust product lineup. In the first half of 2024, Wuling Motors focused on enhancing production lines and processes for motors, motor controllers, and rotors and stators. The H-platform ultra-high-efficiency engine has been successfully commercialized, securing projects with NEV clients like JAC, Changan, and Skyworth. Additionally, Wuling's casting sales reached 515,000 units, up 26.2% compared to the same period in 2023.In the commercial vehicle segment, Wuling focuses on specialized modification markets such as cold chain vehicles, sanitation vehicles, and medical vehicles. Their specialty products, including refrigerated trucks, sanitation trucks, and fire trucks, have been delivered to regions like Shandong, Zhejiang, Hunan, and Beijing. Leveraging its customization capabilities, Wuling has partnered with PepsiCo to develop a "mobile new retail" model, delivering over 100 Wuling vending trucks to PepsiCo and accelerating the expansion of mobile commerce.Wuling's joint venture, Wuling New Energy, is actively upgrading its brand and market position. They launched the long-range Golden Storage Mid-size Logistics Vehicle to quickly capture market share, achieving monthly sales exceeding 1,000 units in the first three months after launch. Additionally, Wuling New Energy is aggressively expanding into international markets, increasing exports to countries such as the USA, Japan, and South Korea. In the first half of 2024, Wuling New Energy sold approximately 7,900 NEVs, a 68.1% increase compared to the same period in 2023.It is evident that Wuling Motors' strategic direction is becoming increasingly clear.With a comprehensive business layout and a full range of products, Wuling has created synergies across its industrial chain, positioning itself as Guangxi's most comprehensive leading automotive group in the supply chain. With unparalleled control over product quality, cost, scale, and customer relations, Wuling has built a formidable competitive advantage.As the NEV era rapidly approaches, Wuling Motors is fortifying its dominant businesses, focusing on high-tech, competitive, and high-end flagship auto parts, expanding markets for high-value specialized modified vehicles, and advancing its NEV key parts and vehicle business.With these foundations, Wuling is boldly venturing overseas, aiming for growth through globalization and efficiency in management, poised for even higher-quality development in the new era. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 8月29日，天津银行召开2024年中期业绩发布会。2024年上半年，天津银行扎实做好金融「五篇大文章」，赋能「新质生产力」，积极践行「四个善作善成」重要要求，聚焦「科技创新、产业焕新、城市更新」「盘活存量、培育增量、提升质量」和天津市「十项行动」，深化法人治理，扎实推进「双五战役」，实现平稳开局，稳中有进，为全年稳健发展奠定良好基础。业务经营形势进一步向好，高质量发展基础进一步夯实经营规模持续增长。资产总额人民币8,973.8亿元，较上年末增长6.7%，其中贷款余额人民币4,414.0亿元，较上年末增长11.5%。负债总额人民币8,304.6亿元，较上年末增长7.1%，其中存款余额人民币4,822.2亿元，较上年末增长7.0%。收入利润实现双增。实现营业收入人民币87.6亿元，同比增长7.7%；实现拨备前利润人民币67.4亿元，同比增长8.1%；实现凈利润人民币19.8亿元，每股收益人民币0.32元。资产质量有效改善。不良贷款率1.54%，较上年末下降0.16个百分点；拨备覆盖率181.75%，较上年末上升13.89个百分点，风险抵补能力不断增强。重点着墨「五篇大文章」报告期内，天津银行已制定「关于做好金融五篇大文章赋能天津高质量发展的实施方案」，协同推进金融「五篇大文章」。搭建科技金融服务体系。作为「科技-产业-金融」新循环试点行，优化科技金融服务模式，整合科技金融产品服务体系，发布「智慧科技通」金融服务方案。科技创新企业贷款余额人民币144.94亿元，较上年末增长24.0%；承销及投资科创票据人民币48.5亿元；打造天津银行系列科创成长基金，推广「一区一基金」模式，三只基金的合作协议已签署落地。推动绿色金融高质量发展。绿色贷款余额人民币330.41亿元，较上年末增长35.69%，发放天津市首笔「企业绿码」挂钩贷款、天津银行首笔EOD模式项目贷款和首笔可持续发展挂钩跨境银团贷款。实现ESG领域债券承销及投资人民币81.11亿元，在交易商协会2024年上半年绿色债务融资工具投资人排行榜中位列城商行第三位。普惠金融向深向实发展。强化金融科技赋能，丰富产品服务体系，稳步提升普惠金融服务效率和水平。涉农贷款余额人民币264.27亿元，较上年末增长23.55%，「智慧富民通」累计放款人民币40.77亿元，惠及6.53万农户。打造「智慧通普惠」数字金融生态服务平台，聚焦小微企业、个体工商户，智慧商户通合作商户120.53万户，较上年末增长21.65%；「智慧商户通·天行用呗」累计放款人民币294.01亿元，较上年末增长49.88%，从源头上解决了个体工商户「融资难、融资慢、融资贵」的难题。打造「金秋港湾」养老金融特色品牌。推出养老金融「专有投资者教育、专属产品货架、有温度的专业服务、专项满意度调研、专注打造特色网点、专策金融支持」「六专」服务体系，营业网点进一步对标适老服务标准，优化适老金融线上服务渠道，举办天津市养老金融暨银发经济专题研讨交流活动。适老储蓄产品余额人民币848.52亿元，较上年末增长8.64%；适老理财产品余额人民币262.01亿元，较上年末增长6.71%；第三代社保卡新增激活8.7万张，网均发卡数量位列天津市第一。深化数字金融助力新质生产力。强化顶层设计，积极践行数字银行建设战略，对外聚焦「服务效能」，对内聚焦「安全生产」，不断提升一体化运营、多元化数据价值释放、智慧化服务再造、数智化营销、综合化事务支撑及智能化风控等能力。培育数字经营新模式，开启企业级全渠道客户数字化运营平台，通过大数据模型实现获客、活客和价值转化能力显著增强，截至报告期末，实际触达基础客户324.65万户，带动手机银行新增客户11.35万户，AUM月日均提升人民币37.60亿元。激发数字金融服务新动能，推出全员作战系统，为战略部署高效执行和职能部门协同作战打造新引擎；通过「数看天行」全面展现经营数据，提升拓客和经营决策效能。加速科技成果积淀转化，年内荣获鑫智奖「数智化转型先锋 企业」等奖项5项，获批17项知识产权。深入践行「四个善作善成」重要要求在发展新质生产力上善作善成。发布「聚力新质生产力发展的工作方案」，旨在以金融力量支持新质生产力加快发展。支持现代产业体系，中长期制造业贷款余额人民币145.28亿元，较上年末增长36.23%，12条重点产业链贷款余额人民币30.69亿元，较上年末增长33.46%。供应链贷款余额人民币126.95亿元，较上年末增长14%，天津地区绿色贷款余额人民币256.01亿元，较上年末增长56.43%。支持科技创新和产业转化，运用「股、债、贷、基、租、保」多元化接力式的综合金融服务，加大对天开高教科创园企业和人才的精准支持。支持盘活用好存量资源，累计为天津市资产盘活领域投放信贷资金人民币385亿元。在全面深化改革开放上善作善成。支持建设高水平开放型经济新体制，聚焦港产城融合发展行动，为滨海新区高质量发展、北方国际航运核心区、「一带一路」提供金融支持。滨海新区对公贷款投放余额人民币511.66亿元，较上年末增长17.54%；支持京津冀协同发展，京津冀地区贷款余额人民币3,405.1亿元，较上年末增长16.4%；累计承销及投资京津冀地区各类债券人民币476.59亿元。与武清区、津南区政府及京津冀16家企业签署战略合作协议，「京津冀产业交流综合金融服务平台」发布上线。在推动文化传承发展上善作善成。支持科教兴市人才强市行动，强化金融与教育领域深度融合，提供贷款融资、智慧校园建设等综合金融服务。打造「运动金融」品牌，发放马拉松主题「悦动卡」和专属理财，理财募集资金已达人民币7.4亿元；「智慧文旅通」「智慧商户通」助力文旅场景拓展，盘活抵羊、利顺德等「老字号、老品牌」，通过商标权、专利权质押的方式为老字号企业提供新增贷款人民币7.4亿元。与佛罗伦萨小镇商圈签署战略合作协议，构建京津冀区域商旅文体农融合特色消费生态圈。将古文化街建设成为天津市「优化支付服务」标杆场景。在提升城市治理现代化水平上善作善成。助力城市更新，制定《支持「中心城区更新提升行动」服务方案》，在城市更新领域提供授信支持人民币37.3亿元。搭建智慧公共服务体系，建设智慧教育通、智慧医疗通，提供全方位的综合性数字化服务方案，推动城市业态、功能、品质不断提升。下一步，天津银行将继续深入贯彻党的二十大、二十届三中全会及中央金融工作会议精神，做好「五篇大文章」，深入践行「四个善作善成」，落实天津市委市政府「三量」「三新」工作要求，服务天津市「十项行动」，为高质量发展注入推动力支撑力。 Copyright 2024 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 30, 2024 - (ACN Newswire via SeaPRwire.com) - On 28 August 2024, Fosun International (HKEX: 0656) announced its 2024 interim results. During the reporting period, its revenue continued to grow, reaching RMB97.84 billion. Industrial operation profit maintained growth, reaching RMB3.47 billion, and profit attributable to owners of the parent was RMB720 million.Guo Guangchang, Chairman of Fosun International, said at the results presentation on the morning of 29 August, “In the first half of the year, although the macro environment remained challenging, we resolutely executed our strategy of focusing on core businesses, developing industry-leading companies and products in the industries where we have formed advantages. Such strategy has been proven effective in general. Looking ahead, we will remain focus on innovation and globalization, while focusing on asset-light operations, driving long-term development with competitive core strengths.”Since the beginning of 2024, the domestic economic recovery has been rocky and the international market has remained volatile, which has brought challenges to Chinese companies including Fosun. Fosun steadfastly pushed forward its strategic focus, driving development with core strengths, achieving quality and efficiency improvement in core industries, and maintaining a solid asset base.Analysts believe that, based on Fosun’s interim results, Fosun’s focus on the core industries in the household consumption sector and its proactive approach to driving innovation and globalization have further reinforced its business foundation, resulting in predictable stable profits. Additionally, over the past two years, Fosun has actively pursued asset-light operations, optimized asset portfolio, and continued to reduce leverage. These efforts have resulted in abundant cash reserves and a stronger financial cushion, which are expected to prompt the market to reassess Fosun’s value.Staying ahead in globalization and innovation, reinforcing business foundation to develop industry-leading companies and products      In the first half of the year, Fosun’s four core subsidiaries, namely Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group (“FTG”), achieved total revenue of RMB72.17 billion, accounting for 74% of the Group’s total revenue. Fosun’s strategy of focusing on core businesses has shown increasing benefits, with its advantages in core industries such as pharmaceuticals, tourism, consumption, and insurance continue to be strengthened.With years of effort in the aforementioned sectors, Fosun has developed a number of industry-leading companies and products.For example, in the first half of this year, Fosun Pharma, which ranks second among the top 100 pharmaceutical companies in China, was selected as one of top 20 global pharmaceutical companies in terms of pipeline scale for the third consecutive year. Shanghai Henlius is the first Chinese profitable innovative biopharmaceutical company listed in Hong Kong, with multiple independently developed monoclonal antibody biosimilars that are driving the rapid development of China’s biopharmaceutical industry. Its first blockbuster product, HANLIKANG, is the first domestic biosimilar approved for marketing. Fosun Insurance Portugal holds the largest market share in the Portuguese insurance market and ranks among the leaders in the insurance sector across Portuguese-speaking regions globally. Easun Technology, in the intelligent manufacturing segment, is a global leading automation and digitalization company.In addition, in the Happiness business segment, Club Med, a subsidiary of FTG, is the global leader that offers exquisite “all-inclusive” holidays. Atlantis Sanya is the leading integrated high-end tourism destination in China, helping to usher Hainan tourism into the 3.0 era. Laomiao Gold, a subsidiary of Yuyuan, is a China time-honored brand and a nationally renowned jewelry brand. These industry-leading companies and products have helped Fosun consolidate its leading position in related sectors.For Fosun, steady and profitable growth is driven by two factors: innovation and globalization.Amid the current domestic economic “involution”, “going global” has become a “must-do” for businesses. Fosun, which began its globalization journey as early as 2007, has become one of the benchmark global companies rooted in China. It has also established a profound industrial presence in more than 35 countries and regions worldwide.During its 17-year globalization journey, Fosun has achieved many successful projects and faced various challenges. Most importantly, this experience has allowed Fosun to develop globalization capabilities that rare among domestic companies. In addition, it has allowed Fosun to connect different markets, industries, and resources globally, achieving global presence, operations and development, while continuously enhancing its global operation capabilities.This is further illustrated by the following data, the Group’s overseas revenue for the first half of 2024 reached RMB45.87 billion, representing a year-on-year increase of 4%, and accounting for 47% of total revenue. Nearly half of the revenue came from overseas, which is rare among Chinese companies.More importantly, Fosun has actively driven the empowerment and synergy of its corporate ecosystem in the course of globalization. Its domestic and overseas member companies have made significant progress in global research and development (R&D), business expansion, operations, and investment and financing.For example, HANQUYOU, independently developed by Fosun’s subsidiary Shanghai Henlius, received marketing approval from the United States (U.S.) Food and Drug Administration (FDA), making it a “Chinese” monoclonal antibody biosimilar approved in China, the European Union (EU), and the U.S. HANLIKANG, China’s first biosimilar, received marketing approval from the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru, making it the third self-developed drug of Shanghai Henlius to be approved for overseas marketing after HANQUYOU and HANSIZHUANG.Moreover, Club Med, a subsidiary of FTG that operates 67 resorts worldwide, achieved a record-high business volume of RMB8.89 billion in the first half of 2024, representing a year-on-year increase of 10.3%. Club Med’s business in the Europe, Middle East and Africa (EMEA) region and the Americas continued to grow, and its business in Asia-Pacific region recovered significantly. In May 2024, Club Med signed an agreement in Oman for the launch of its first resort in the Middle East.Fosun Insurance Portugal, which began its operations in Portugal, has been actively expanding into overseas markets. In the first half of 2024, it achieved business growth domestically and internationally. The contribution from overseas markets further increased, with international business recording premiums of EUR885 million, accounting for over 30% of the total premiums; the net profit of international business was approximately EUR51 million, accounting for over 40%.Easun Technology, a global leading automation and digitalization company under Fosun, has also been advancing its overseas expansion. In the first half of 2024, it achieved new overseas orders of RMB3.99 billion, with a significant increase in orders from the U.S. market, reaching RMB750 million, more than doubling year-on-year.Innovation is also a core competence that Fosun has accumulated over a long period of time and has always adhered to. During the reporting period, Fosun invested a total of RMB3.5 billion to deepen its technological and innovation capabilities. Its integrated innovation model under a global vision has become more mature, resulting in a number of ground-breaking achievements that are steadily generating profits and driving Fosun’s growth.In terms of innovative drug R&D, Fosun Pharma has 4 products with a total of 9 indications were approved for marketing; 4 products with a total of 9 indications had entered the pre-launch approval stage/key clinical stage; and 9 products (by indication) have been approved to conduct clinical trials. Shanghai Henlius’ independently developed and manufactured innovative biologics continue to make breakthroughs. The world’s first anti-PD-1 monoclonal antibody for the first-line treatment of small cell lung cancer (SCLC), HANSIZHUANG, has been approved for 4 indications, benefiting over 75,000 patients. It has also been out-licensed to over 70 countries and regions, including the U.S., Europe, Southeast Asia, the Middle East, and North Africa. In addition, the new indication for SUKEXIN, a new generation of oral thrombopoietin receptor agonist (TPO-RA), has been approved by the National Medical Products Administration (NMPA).New progress has also been made in the deployment of cutting-edge medical devices and innovative therapies. In June 2024, Intuitive Fosun Headquarters Industrial Base was inaugurated in Shanghai. It is the largest integrated R&D, production and training base of Intuitive Surgical in the Asia-Pacific region, significantly accelerating the localization of the da Vinci surgical robot. Intuitive Fosun’s Ion robotic bronchoscopy was approved by the NMPA in March this year and was launched in July 2024.“Asset-light operations” taking shape, poised for revaluationBenefitting from the strong support in its business operations, Fosun’s financials have also continued to improve. During the reporting period, Fosun continuously optimized its asset portfolio, continuously reduced leverage, and maintained a sound financial position. As of 30 June 2024, the Group’s adjusted total debt-to-capital ratio was 50.2%, maintaining a downward trend since 2020. Adjusted NAV was HK$17.4 per share, indicating that Fosun International’s current share price is significantly undervalued.Meanwhile, Fosun has actively strengthened its financial cushion and maintained ample cash reserves. As of 30 June 2024, Fosun International’s cash and bank balances and term deposits reached RMB109.55 billion, representing an increase of RMB17.1 billion compared to the end of 2023. In the 17 years since its listing, Fosun has accumulatively paid out HK$25.6 billion in dividends, with the dividend payout ratio gradually increasing to over 20% in the past five years.In June 2024, the international rating agency S&P fully recognized the effectiveness of Fosun’s financial strategy and affirmed its rating outlook as “stable”.While achieving stable profits through ongoing innovation and globalization, Fosun has also responded to the new market environment by streamlining its business. It has progressively exited some non-core industries and has actively advanced its asset-light strategy, which is now taking shape.In May 2024, Fosun sold all of its 99.74% stake in the German private bank HAL, which attracted market attention. After the completion of the transaction, Fosun will no longer hold any shares in HAL, but will retain the HAFS asset servicing business, managing approximately EUR100 billion in assets in an asset-light operation model.In the tourism sector, Fosun’s asset-light operation model has achieved remarkable results, with IPs such as Club Med, Atlantis Sanya, and Taicang Alps becoming benchmarks in the domestic tourism industry. In the first half of 2024, 85% of Club Med resorts adopted a leasing and management model, with the proportion of self-owned resorts declining to 15%.In April 2024, the AMAZE Snow Mountain Camp, FTG’s new IP in Lijiang Club Med Resort, quickly became a hit after its opening, driving significant occupancy increases at the nearby Club Med Lijiang Resort and Joy Holiday Hotel Lijiang.In June 2024, FTG joined hands with the Taicang Municipal Government to build the phase II of Taicang Alps Resort, a one-stop ice and snow-themed urban tourist destination. The phase II project, with a total investment of over RMB5 billion, is funded by the Taicang Municipal Government and operated and managed by FTG. The successful operation of the Alps Snow Live has provided confidence and momentum for the phase II project, which is expected to set several world records in ski resorts.Fosun has also joined hands with partners to set up a number of industry funds to drive the future of advantageous industries. In March 2024, leveraging its leading advantages in biomedicine, Fosun Pharma joined hands with Shenzhen Guidance Fund and seven other investors to jointly establish a RMB5.0 billion biomedical industry fund, with all proceeds to be invested in biomedical, cells, genes, etc. Shanghai Fujian Equity Investment Fund Management, a subsidiary of Fosun Pharma, was selected through public selection process in Shenzhen to exclusively manage this fund. In April this year, the Shenzhen Municipal Government and Fosun signed a strategic cooperation framework agreement, both parties will further strengthen cooperation in areas such as biomedicine, cultural and sports tourism, and fashionable consumption.In addition, Fosun Capital, together with Wuhan Innovation Investment and Wuhan Fund, established a RMB3.0 billion industry fund with an initial scale of RMB1.1 billion in April 2024. This is the first batch of market-oriented fund invested by Hubei Province since the establishment of the RMB20.0 billion government guidance fund, mainly focusing on the four major sectors of new generation information technology, dual carbon, intelligent manufacturing, and consumption.Given the current market environment, it is expected that Fosun will continue to focus on asset-light operations, continuously expand its “circle of friends”, strengthen in-depth cooperation with all parties, and achieve win-win results through complementing each other’s advantages.Market analysts believe that Fosun has achieved sustained and stable profits leveraging its core strategies of innovation and globalization. In addition, by exiting non-core assets, pursuing asset-light operations, and continuously reducing debt, Fosun has maintained robust financial health, paving the way for a potential market revaluation.Guo Guangchang believes that in the future, investors will place greater emphasis on the growth of core industries and the stability of cash flow. “One-off asset sales are only short-term solutions. The growth of core businesses is crucial for a company to achieve stable profits.” Fosun aims to build a consumer group centered on core industries, ensuring more predictable business development and profits. At both the group level and within each business unit, Fosun is committed to creating value for its customers and investors that is manageable in terms of risk and promotes steady growth. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 近日，中国光大环境（集团）有限公司（257.HK）（下称“光大环境”或“公司”）公布了2024中期业绩。作为一站式、全方位的环境综合治理服务商，光大环境不仅保持业务稳健增长，更在环境保护和社会责任方面发挥重要作用，引领行业标杆。绿色科创赋能未来 广泛推动绿色合作光大环境积极参与高层行业对话和国际论坛，推动区域环境合作。2024年上半年，公司管理层先后出席了美丽中国百人论坛2024年会、上海合作组织国家绿色发展论坛。在上海合作组织国家绿色发展论坛上，光大环境与各国代表共同探讨绿色发展战略，为全球绿色发展贡献中国方案。论坛期间，光大环境总裁栾祖盛参与了“产业集聚共建繁荣上合”主题环节，并以《发展绿色生产力 共建可持续未来》为题发言，重点分享了开展务实科技交流，构建绿色创新生态圈；推动低碳产能合作，打造绿色产业聚集区；加快标志项目落地，树立绿色上合新标杆三方面的思考。此外，公司作为参建单位受邀还出席了海南博鳌近零碳示范区运行启动会。今年上半年，公司旗下越南顺化垃圾发电项目竣工仪式获越南国家政府总理出席，同时，公司亦受邀出席越南总理与在越中资企业的座谈会，展示了中国企业在“一带一路”倡议下的担当和影响力。公开透明沟通 提升市场形象秉持开放透明的原则，光大环境主动接受各界监督，展现了高度的企业责任感和治理水平。2024年上半年，公司组织了近20次项目考察活动，吸引逾百家境内外投资机构参加。这些考察活动涵盖了公司在垃圾发电、水环境治理、生物质能利用等多个领域的代表性项目，让投资者、分析师和媒体代表深入了解了光大环境的运营模式、技术创新和发展战略。通过面对面交流和实地考察，公司深化了与各利益相关方的沟通，增进了相互理解和信任。这种开放、透明的沟通策略不仅提升了公司的市场形象，也为吸引更多投资者和合作伙伴奠定了坚实基础。截至2024年6月30日，已有23家机构给予光大环境正面评级，公司股价较2023年底升逾50%。倡导环保低碳 携手各界筑绿光大环境积极推动环保宣传，致力于提升公众的环保意识和参与度。在内地，公司围绕“世界水日”、“世界环境日”等重要环保主题日，在全国各地的项目公司组织开展了形式多样、内容丰富的环保活动。在日常亦通过策划并组织主题形式多样的公益活动，深入当地社区，与民众互利共融，吸引了大量市民参与，有效普及了环保知识，培养了公众的环保习惯。截至2024年6月30日，光大环境累计有220个项目向公众开放，线下接待境内外各界参观考察人士约9,500人次，参与和观看线上活动的人数约8万人次。获颁多项荣誉，巩固行业影响力2024年上半年，光大环境凭借卓越的经营业绩和社会贡献，收获多项荣誉。公司连续13年位居中国“年度固废十大影响力企业”榜首，获标普第七次纳入《可持续发展年鉴》；旗下光大水务连续7年入选“中国水业十大影响力企业”榜单；光大绿色环保更是第3次获评《亚洲周刊》全球卓越ESG大奖。这些荣誉和成就进一步巩固了光大环境在环保领域的领军地位，为公司未来的发展注入了强劲动力。面对国家“双碳”目标和对照中国式现代化建设目标要求，作为行业领军企业，光大环境在推动绿色低碳发展、改善生态环境质量、促进经济社会可持续发展等方面发挥了重要作用。公司管理层表示，未来，光大环境将继续秉持“创造更好投资价值，承担更多社会责任”的企业使命，坚持创新驱动，深化国际合作，不断提升环境治理能力和水平，为中国生态文明建设和全球可持续发展贡献更大力量。 Copyright 2024 亚太商讯 via SeaPRwire.com.

香港, 2024年8月30日 - (亚太商讯 via SeaPRwire.com) — 渤海银行股份有限公司（「渤海银行」或「公司」；股份代号：9668.HK）宣布公司及其附属公司（「集团」）截至2024年6月30日止六个月（「报告期」）之未经审计综合中期业绩。2024年上半年，国际环境更趋复杂严峻，主要经济体经济增长与货币政策有所分化。中国经济运行延续回升向好态势，高质量发展扎实推进，但仍面临有效需求不足、企业经营压力较大、重点领域风险隐患较多等困难。集团全面落实监管政策要求，坚持稳中求进工作总基调，以进促稳，先立后破，持续推进「十个专项工作」攻坚，扎实落地高质量发展方案各项目标任务，优化业务布局，狠抓科技创新，突出转型驱动，强化风险防控，在转方式、调结构、提质量、增效益上积极进取，推动高质量发展取得新成效。报告期内，集团实现营业收入131.45亿元，净利润36.97亿元，总体保持了平稳发展态势。截至报告期末，资产总额17,479.96亿元，较上年末新增152.62亿元，增幅0.88%。其中，发放贷款和垫款总额（未含应计利息）为9,478.52亿元，较上年末新增152.08亿元，增幅1.63%；负债总额16,294.25亿元，较上年末新增110.94亿元，增幅0.69%。其中，吸收存款总额（未含应计利息）9,346.22亿元，较上年末新增194.60亿元，增幅2.13%；不良贷款余额为171.12亿元，比上年末增加5.54亿元；不良贷款率为1.81%，比上年末上升0.03个百分点。贷款损失准备计提充足，贷款减值准备271.07亿元，比上年末增加11.20亿元。贷款拨备率2.86%，拨备覆盖率158.41%，均符合监管要求。回归服务实体经济本源  扎实推进公司银行业务高质量转型报告期内，公司银行以服务国家战略目标和实体经济为根本宗旨，紧紧围绕做好科技金融、绿色金融、普惠金融、养老金融、数字金融五篇大文章，坚持行业银行、交易银行、轻型银行定位，优化业务结构，提升经营水平，扎实推进公司银行业务高质量转型发展。客户建设方面，报告期内，公司银行坚持以客户为中心，持续完善行业战略客群、基础专项客群、政府机构客群、区域重点客群等四大对公客群服务体系。截至报告期末，公司银行全量客户合计111,472户，比上年末增加6,040户，增长5.73%。负债业务方面，公司银行始终坚持「存款为本」的理念，通过传统及非传统信贷产品组合应用，搭建业务场景，为客户提供综合金融服务，积极拓展低成本存款。同时，推进数字化系统建设，完善产品功能，提升服务水平，优化客户体验，推动存款规模增长和存款结构优化。截至报告期末，公司存款总额5,942.76亿元，比上年末增加281.09亿元，增长4.96%。资产业务方面，公司银行围绕服务实体经济，持续加大对科技金融、制造业、绿色信贷、乡村振兴等重点领域的支持力度。制造业、科创类小微企业、绿色金融、涉农等重点领域贷款增速均大幅高于一般性贷款增速。截至报告期末，公司贷款总额6,366.66亿元，比上年末增加699.26亿元，增长12.34%。科技企业贷款余额438.95亿元，其中专精特新企业贷款余额同比增长23.03%，高技术产业贷款余额同比增长22.08%，知识产权密集型产业贷款余额同比增长12.79%；制造业贷款余额912.79亿元，较上年末增长6.84%；绿色贷款余额377.45亿元，较上年末增长20.75%；涉农贷款余额419.16亿元，较上年末增长15.62%。交易银行业务方面，交易银行持续加强产品化、场景化、线上化建设，围绕供应链金融、票据服务、现金管理解决方案、国际结算与贸易融资，构筑交易银行业务生态，深挖客户需求，为客户提供一站式服务体验。报告期内，交易银行实现非息收入9.60亿元，同比增长5.73%。其中，价差收入1.43亿元，同比增长268.98%。交易银行业务表内外资产规模4,707.4亿元， 同比增长14.17%；累计投放4,347.77亿元，同比增长78.23%。全行线上公司业务客户数13,286户，新一代票据业务活跃客户数2,109户。实现国内信用证及福费廷业务投放1,163.61亿元。海纳池累计投放金额124.19亿元，在池资产规模156.54亿元。投资银行业务方面，集团坚定FPA经营发展转型方向，着力打造流量银行，盘活存量、用好增量、做大流量，以具有比较优势的钩子产品作为业务破局点，将服务经济融资总量作为工作的出发点和落脚点，持续优化业务结构、丰富收入来源、发力渠道拓展、夯实客户基础，强化通过债券承销、交易撮合、资产流转、理财子公司对接等高效利用资本方式实现拓展客户、沉淀存款、提升效益的能力。2024年上半年，投资银行债券主承销业务规模913.56亿元，同比增长105.48%；累计承销各类创新债券（含结构化融资产品）31只，承销金额合计120.17亿元。交易撮合业务稳步发展，报告期内，撮合对接资产规模433.25亿元，同比增长5.78%。资产托管业务方面，报告期内，资产托管业务扎实履行服务实体经济高质量发展职能，坚持专业化、规范化发展，持续优化运营流程，夯实客户基础，探索创新服务模式，推动托管规模快速提升。截至报告期末，资产托管及外包业务规模余额28,058.55亿元；报告期内，实现资产托管及外包业务收入15,417.77万元。根据中国银行业协会2024年第二季度统计数据，集团托管规模排名第20位。普惠金融业务方面，报告期内，集团重点聚焦普惠金融产品谱系打造，着力构建「链系列、数系列、快系列、科系列」四大普惠金融产品谱系，实现线上线下相结合，大幅提升服务效率和客户体验，打造具有渤海特色的普惠服务品牌。截至报告期末，集团普惠贷款余额457.35亿元；普惠贷款客户数87,402户；当年累放贷款执行利率4.4%。着力打造账户银行、财富银行、生态银行  零售银行业务稳步发展报告期内，零售银行着力打造账户银行、财富银行、生态银行，推进「账户+支付+金融产品」的综合服务体系建设，强化生态拓客模式，依托技术支撑和数字驱动，深化客户分层分群经营，以客户视角聚合产品服务，优化产品谱系，改善业务结构，推进零售业务稳步发展。截至报告期末，集团零售存款余额2,103.19亿元，较上年末增加93.17亿元。客户发展方面，集团加快数字化运营能力突破，聚焦多元渠道建设、拓客模式转型和生态场景搭建，完善客户分层分群经营服务策略，优化代发和支付服务工具，促进零售客户增量提质。截至报告期末，集团零售客户总量793.18万户，较年初净增21.93万户。资产业务方面，报告期内，零售资产业务以国家信贷政策为导向，加快推进业务高质量转型发展，坚持以客户为中心，满足客户多样化信贷需求。截至报告期末，个人贷款余额2,247.65亿元。财富管理方面，持续打造「渤银E财」产品货架，提升产品供应能力。报告期内，零售财富资产规模稳步提升，同比增长407.24%，其中代销理财存量规模增速较上年同期提升26.25个百分点，代销信托存量规模同比增长116.14%，发展势头良好。私人银行专业化服务成效日益凸显，截至报告期末，私人银行投资理财类产品的覆盖度较年初提升1.23个百分点。信用卡业务方面，集团聚焦金领贷客群、房贷客群，将信用卡打造成为增强零售优质客群粘性的有效载体。截至报告期末，信用卡累计发卡量126.42万张，贷款规模41.89亿元。提升金融市场业务创新转型发展能力  树立行业口碑报告期内，集团金融市场业务坚决践行转型振兴高质量发展要求，以建设市场领先的金融市场FICC业务中心为目标，牢牢守住风险底线，深耕同业客户基础，强化销售交易能力建设，确保全行流动性安全，金融科技赋能业务发展，坚持金融服务实体经济，各项工作取得显著成果。理财业务方面，集团持续丰富理财产品种类，优化产品功能，为客户提供更好的理财服务。同时积极拓展行外代销渠道，拓宽资产管理服务客群，已与26家机构达成代销合作。报告期内，集团共发行理财产品204只，销售金额合计2,048.85亿元。截至报告期末，集团存续理财产品358只，理财产品余额1,677.01亿元，净值型产品占比91.72%。资金业务方面，密切关注市场走势，加强市场研判，积极开展各类货币市场交易业务，上半年开展人民币债券质押式回购交易约5.57万亿元，同比增长5.96%，获得中国人民银行2024年度公开市场业务一级交易商资质，并获评中国外汇交易中心回购活跃交易商，大幅提高银行间市场影响力。同时，紧抓市场机遇，踊跃参与外汇交易中心各类标准化交易业务，外汇交易各项排名较上年同期均有不同程度的提升，其中人民币外汇掉期交易排名跻身银行间市场45强。债券业务方面，持续加强债券业务模式和产品创新，做大债券投资交易规模，债券市场影响力、货币政策传导能力、双边做市服务能力有效提升。报告期内，各类金融市场债券业务量保持稳步增长，现券交易量2.9万亿元，同比增长70%。同业业务方面，集团持续探索并推进同业客户一体化经营。继续完善同业产品货架，以销售促转型稳步推进，客户综合贡献稳步提升，同业朋友圈更加丰富完备。报告期内，实现属地目标同业客户覆盖率43.4%，多元产品渗透率34.81%。同业授信方面，报告期内，境内外同业机构对集团授信额度充足、品种广泛，满足全行各项业务稳定发展需要。截至报告期末，集团累计获得超过1,300家同业机构授信，授信总额1.6万亿元人民币。聚焦数字金融和智慧金融  持续推进网络金融业务报告期内，集团网络金融业务聚焦数字金融和智慧金融，持续推进线上用户运营和门户渠道建设，通过技术与数据赋能，加速实现综合化服务升级和经营转型发展。手机银行方面，集团重点围绕账户银行、财富银行和生态银行战略定位，逐步从功能建设向客户经营转型并成功升级至6.3版，通过建立事件型营销体系和数字化全域经营促进移动端月活客户数量和财富产品成交量持续提升。门户网站方面，集团于2024年5月完成门户网站系统重构，实现全面升级，为客户提供智能化服务新体验。在生态化经营方面，集团持续深耕教育服务场景，深化场景化服务新模式，打造全方位服务客户的生态体系。展望未来2024年下半年，集团将全面落实监管政策要求，遵金融规律、守金融向善、求金融真实，以改革精神做强主责主业，更加注重统筹联动，更加注重突出重点，更加注重实绩实效，持续集中全力转方式、调结构、提质量、增效益，努力开创高质量发展新局面。 Copyright 2024 亚太商讯 via SeaPRwire.com.